LBX₄

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: LBX₄
• 英文别名: 15-epi-LXB4；15R-5,14,15-trihydroxy-6,10,12-trans-8-cis-eicosatetraenoic acid；epi-Lipoxin B4；(5S,6E,8Z,10E,12E,14R,15R)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid
• 化学式: C₂₀H₃₂O₅
• 分子量: 352.471
• InChiKey: UXVRTOKOJOMENI-SKYGSKSRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Benzo Lipoxin Analogues
  申请人：PETASIS Nicos A.

  公开号：US20120142772A1

  公开（公告）日：2012-06-07

  Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.

  本文提供苯唑环氧化物类似物的制备方法和含有该化合物的药物组合物。这些化合物和组合物在治疗各种疾病，包括炎症、自身免疫性疾病和异常细胞增殖的方法中有用。
• Lipoxin compounds and their use
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：EP1586550A1

  公开（公告）日：2005-10-19

  Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.

  阿司匹林（ASA）通过乙酰化环氧化酶 II，触发脂质介质生物合成的开关，抑制类前列腺素的生成，并启动 15-epi-lipoxin 的生成。
• Compositions and methods relating to salts of specialized pro-resolving mediators
  申请人：Thetis Pharmaceuticals LLC

  公开号：US10130719B2

  公开（公告）日：2018-11-20

  The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold moiety as described herein, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

  本发明涉及的化合物是特异性促溶解介质（本文称为 "SPMs"）的盐，其中包括脂质素、溶血素、保护素及其阿司匹林触发的对应物。本文所述的 SPM 盐含有至少一个或两个与本文所述的支架分子提供的至少一种基本功能离子结合的 SPM 分子、含有相同成分的组合物以及使用相同成分治疗以慢性或过度炎症为特征的各种疾病和失调或两者兼而有之的方法。
• Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
  申请人：Solutex NA LLC

  公开号：US10653703B2

  公开（公告）日：2020-05-19

  The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.

  本发明涉及一种多不饱和脂肪酸组合物，该组合物由 Omega-3 脂肪酸、17-HDHA 和 18-HEPE 组成。该组合物还可进一步包含 DPA 和/或可接受的载体，并可以胶囊或其他合适的剂量单位形式存在。本发明还涉及获得该组合物的过程以及使用该组合物的方法。
• Prevention of neutrophil recruitment
  申请人：Serhan N. Charles

  公开号：US20050192350A1

  公开（公告）日：2005-09-01

  Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.

  阿司匹林（ASA）通过乙酰化环氧化酶 II，触发脂质介质生物合成的开关，抑制类前列腺素的生成，并启动 15-epi-lipoxin 的生成。